US FDA Panel Divided In Support Of Ipsen’s Rare Bone Disorder Drug Palovarotene

 
• By Brenda Sandburg

Advisory committee members voted 10-4 that a Phase III study showed evidence of drug efficacy even though it did not meet its primary endpoint. Panelists cited devastating progression of the disease and need for more data from a patient registry.

Bone disorder
Drug to treat rare bone growth disorder gets mixed review from FDA advisory committee. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers